Human Albumin Csl Behring (Human Plasma Protein)

Human Albumin Csl Behring is a sterile intravenous solution that contains human plasma protein (human albumin) as its active ingredient. It is supplied in a standard concentration for clinical use within the European Union. The product is administered by healthcare professionals under prescription and is classified as a plasma volume expander to support patients with low plasma protein or fluid loss and related conditions during acute care.

Human Albumin Csl Behring is indicated for clinical situations where plasma volume expansion or replacement of albumin is required. It is commonly employed in the management of hypovolemia, hypoalbuminemia, severe burns, and circulatory shock.

- Treatment of hypovolemia due to blood loss or fluid depletion. - Management of hypoalbuminemia associated with liver disease or nephrotic syndrome. - Supportive care for patients with extensive burns to maintain intravascular volume. - Resuscitation in circulatory shock when rapid plasma expansion is needed. - Adjunct therapy during major surgery to preserve oncotic pressure.

Adverse reactions to Human Albumin Csl Behring are generally infrequent but may occur following intravenous administration.

Common: - Transient fever or chills. - Mild headache. - Nausea or vomiting. - Localized infusion site erythema.

Serious: - Anaphylactic or severe allergic reaction. - Acute hemolysis. - Volume overload leading to pulmonary edema. - Thromboembolic events.

Healthcare providers should evaluate patient history and clinical status before administering Human Albumin Csl Behring to minimize risk.

- Assess for known hypersensitivity to human albumin or any plasma-derived products. - Use caution in patients with congestive heart failure or renal impairment due to risk of volume overload. - Monitor fluid balance and vital signs during and after infusion. - Avoid rapid infusion rates; adhere to recommended administration guidelines. - Consider alternative volume expanders in patients with active infection or sepsis. - Evaluate coagulation status in patients receiving anticoagulant therapy.

Human Albumin Csl Behring may interact with other medications or clinical conditions that affect fluid balance or immune response.

Avoid: - Concomitant use of high‑dose diuretics that may exacerbate hypovolemia. - Simultaneous administration of other plasma protein products without clear indication. - Rapid infusion of hypertonic solutions that could increase osmotic stress.

Use with caution: - Concurrent anticoagulants or antiplatelet agents, monitoring for bleeding. - Vasopressor therapy, as volume status may alter drug efficacy. - Immunosuppressive agents, due to potential altered immune response.